Nanosystems for Targeted Therapy and Molecular Immunosensing of Ovarian Cancer (seminar postponed from June 17, 2013)
Event details
| Date | 01.07.2013 |
| Hour | 14:00 › 15:00 |
| Speaker |
Prof. Yadollah Omidi, Ovarian Cancer Research Center, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA (USA) Bio: Dr. Omidi is Associate Professor of Pharmaceutical Nanobiotechnology and Drug Targeting. He holds a pharmacy doctorate degree (1991) from Tabriz University of Medical Sciences (TUOMS) and a Ph.D. degree (2003) from Cardiff University. He has postdoctoral research associate experience (2002-2004) working on gene-based nanomedicines and toxicogenomics in the Center for Genome-based Therapeutics at Welsh School of Pharmacy, Cardiff University. From 2004 till 2011, he has worked as associate professor at TUOMS Faculty of Pharmacy and also founded the Research Center for Pharmaceutical Nanotechnology (RCPN), ranked as the number one center of excellence in Iran (2008-2011), and the School of Advanced Biomedical Sciences. Since 2008, Dr. Omidi is a member of the National Academy of Medical Sciences of Iran and is recipient of the Razi Festival Award for advancing biomedical research. In July 2011, he joined the Ovarian Cancer Research Center (OCRC) at University of Pennsylvania as a Visiting Associate Professor to develop/advance translational nanomedicines focusing on multifunctional nanomedicines and theranostics for simultaneous diagnosis and therapy of cancer. Dr. Omidi has published over 80 papers and more than 10 book chapters. |
| Location | |
| Category | Conferences - Seminars |
Most of ovarian cancer (OC) patients are diagnosed in the late stage of the disease when it has already disseminated beyond the ovaries, while the currently used treatment modalities often fail to effectively cure the disease. Thus, OC patients need to be diagnosed at the early stage and efficiently treated with targeted therapies using synthetic lethality. Here, we present engineered nanosystems (NSs) for targeted therapy and molecular immunosensing of OC. For targeted therapy, we engineered biodegradable nanoparticles (NPs) of poly(lactic-co-glycolic acid) containing cytotoxic agents or drugs inhibiting OC cells transporters involved in pH dysregulation to simultaneously target key molecular elements of OC within tumor microenvironment. The NPs were decorated with polyethylene glycol and anti-tumor endothelial marker 1 (TEM1) antibody (Ab)/scFv. These NSs (220 nm) showed sustained-release profile and actively inhibited TEM-1 expressing MS-1 endothelial cells and OVCAR-5 cells. For molecular sensing, we capitalized on preparation of improved immunosensor to sense CA125 expressed by OC cells and found in OC patients serum. To amplify the sensing signals, surface of the electrodes were decorated with NPs (20 nm) that were armed with anti-CA125 Ab using silica coated gold NPs or CdSe quantum dots. The engineered immunosensors were successfully tested using EIS and CV methods showing high precision. These NSs may be used for successful detection and effective therapy of OC as well as other solid tumors.
Links
Practical information
- Informed public
- Free
- This event is internal
Organizer
- Prof. Melody Swartz
Contact
- Institute of Bioengineering (Dietrich Reinhard)